Low-dose ouabain administration increases Na+,K+-ATPase activity and reduces cardiac force development in rats

• Published in: Pharmacological reports Vol. 67; no. 2; pp. 253 - 259
• Main Authors: Meira, Eduardo F., Siman, Fabiana Dayse M., Faria, Thais de O., Júnior, Rogerio F. Ribeiro, de Batista, Priscila R., Stefanon, Ivanita, Vassallo, Dalton V., Padilha, Alessandra S.
• Format: Journal Article
• Language: English
• Published: Cham Elsevier Urban & Partner Sp. z o.o 01.04.2015; Springer International Publishing
• Subjects: Animals; Blood Pressure - drug effects; Calcium-Binding Proteins - metabolism; Drug Safety and Pharmacovigilance; Hypertension; Isoproterenol - pharmacology; Male; Myocardial Contraction - drug effects; Myocardial Contraction - physiology; Myocardium - metabolism; Na+,K+-ATPase activity; Original Research Article; Ouabain; Ouabain - administration & dosage; Ouabain - pharmacology; Papillary muscles; Papillary Muscles - drug effects; Papillary Muscles - physiology; Pharmacotherapy; Pharmacy; Rats; Sarcoplasmic Reticulum Calcium-Transporting ATPases - metabolism; Sodium-Calcium Exchanger - metabolism; Sodium-Potassium-Exchanging ATPase - metabolism; Stimulation, Chemical; Hypertension; Na+,K+-ATPase activity; Papillary muscles; Ouabain; Na; K; ATPase activity; Na(+),K(+)-ATPase activity

Ouabain is a digitalis compound that inhibits the Na+,K+-ATPase (NKA) activity inducing increment in cardiac force. However, this effect seems to be dose dependent. At low concentration, ouabain can induce an increase of NKA activity. We investigated the effects of ouabain administration (25μg/kg/da...